ReCor Medical’s Paradise renal denervation catheter uses heat (depicted by the red ring) from ultrasound-generated energy for denervation, while cooling with circulating water (depicted by the blue rings) within the artery to protect it from heat. [Illustration courtesy of ReCor Medical]
ReCor Medical is hiring as its Paradise ultrasound renal denervation (RDN) system seems set for regulatory approval following this week’s favorable vote by an FDA review panel.
The Circulatory Systems Devices Panel of the FDA’s Medical Devices Advisory Committee voted in support of the Paradise system’s safety, efficacy and risk/benefit profile for patients with uncontrolled hypertension.
Such a vote is usually a precursor to FDA premarket approval (PMA). The same panel of experts dashed Medtronic’s hopes of securing a PMA for its competing Symplicity Spyral RDN system the following day.
If approved by the FDA, ReCor’s minimally invasive RDN system would be the first on the market in the U.S., addressing a large population of patients who can’t manage their high blood pressure with medication. Hypertension is a significant risk factor for heart attacks and strokes.
Related: Device design and development tips for the future of stroke care
Executive hires at ReCor Medical
ResCor Medical CEO and President Lara Barghout [Photo courtesy of ResCor Medical]
Palo Alto, California-based ReCor Medical — a subsidiary of Tokyo-based Otsuka Medical Devices — has already made high-level hires this year in anticipation of U.S. commercialization.
In January, ReCor Medical hired Lara Barghout as CEO and president. She was previously SVP and head of advanced therapies at Siemens Healthineers, and before that held executive roles at Terumo Cardiovascular, ultimately rising to SVP of global commercial operations.
Michael Jones joined ReCor Medical’s C-suite as chief financial officer in June. He was previously CFO at Sense Biodetection, where he helped the diagnostics developer build infrastructure and ramp up manufacturing in preparation for U.S. commercialization.
Other senior hires in 2023 included North America GM Ryan Byars (formerly of Biotronik Vascular, Boston Scientific and Bausch & Lomb Surgical) and HR VP Ricky Robinson, who held executive human resources roles at Medtronic before serving as chief people officer for Boeing’s Wisk Aero autonomous vertical-takeoff-and-landing air taxi subsidiary.
ReCor Medical job postings
The newest of ReCor Medical’s recent job postings on LinkedIn is for the position of staff quality systems engineer.
The company’s jobs website also lists several operations roles for process control development, test and validation development, catheter manufacturing engineering and a supply chain materials specialist.
ReCor Medical is also advertising roles across the country for building the business, including clinical specialists, sales territory managers, regional sales directors, therapy development territory managers, field reimbursement managers and a director of sales operations, insights and customer experience.
Other job postings supporting commercialization include senior director of compliance, commercial financial planning and analysis (FP&A) manager, clinical business systems analyst and senior director of key opinion leader (KOL) management.
“Our team is growing fast,” Chris Fetter, a 15-year Boston Scientific veteran who joined ReCor this month as director of therapy development, wrote on LinkedIn. “Come join the ride.”
Related: How does medtech CEO pay stack up to the rank and file?